TGTX insider buying and SEC filings, explained
TG Therapeutics, Inc. · CIK 1001316
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$438K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 10, 2026 | Sale | Laurence N Charney (Director) sold 5,000 shares at about $54.96 ($275K). Holdings down 3% to 168,640 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 14, 2026 |
| Nov 24, 2025 | Sale | Yann Echelard (Director) sold 5,000 shares at $32.57 ($163K). Holdings down 2% to 223,816 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 25, 2025 |
10 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TGTX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.